Aurinia Files Form S-8 to Register Shares Underlying Previously Disclosed Inducement Awards for Newly Hired Employees
26 Maio 2023 - 6:16PM
Business Wire
Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) (Aurinia or the
Company) today announced the filing of a registration statement on
Form S-8 with the United States Securities and Exchange Commission
(SEC).
Under U.S. federal securities laws, equity awards issued as
employee compensation must be registered under the Securities Act
of 1933, as amended, via an S-8 registration statement or qualify
for an exemption from registration. This Form S-8 registers
previously issued and disclosed stock options and restricted stock
units (RSUs) that were granted as inducement awards to employees
entering employment with Aurinia in accordance with Nasdaq Listing
Rule 5635(c)(4).
Aurinia will not receive any proceeds from any sales of shares
underlying such equity awards by the employees that are registered
under this Form S-8. However, upon the exercise of stock options
exercisable for shares covered by the Form S-8, Aurinia will
receive the proceeds from such exercise. Under SEC rules and
regulations for the shares underlying equity awards to be freely
tradeable, an S-8 registration statement must be filed. The filing
is administrative in nature and solely relates to equity awards
(options and RSUs) that have already been publicly disclosed.
This press release shall not constitute an offer to sell or a
solicitation of an offer to buy these securities nor shall there be
any sale of these securities in any state or jurisdiction in which
such offer, solicitation or sale would be unlawful prior to
registration or qualification under the securities laws of any such
state or jurisdiction.
About Aurinia
Aurinia Pharmaceuticals is a fully integrated biopharmaceutical
company focused on delivering therapies to treat targeted patient
populations with a high unmet medical need that are impacted by
autoimmune, kidney and rare diseases. In January 2021, the Company
introduced LUPKYNIS® (voclosporin), the first FDA-approved oral
therapy for the treatment of adult patients with active lupus
nephritis (LN). The Company’s head office is in Edmonton, Alberta,
its U.S. commercial hub is in Rockville, Maryland, and the Company
focuses its development efforts globally.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20230526005325/en/
Investors: Aurinia@westwicke.com
Aurinia Pharmaceuticals (NASDAQ:AUPH)
Gráfico Histórico do Ativo
De Abr 2024 até Mai 2024
Aurinia Pharmaceuticals (NASDAQ:AUPH)
Gráfico Histórico do Ativo
De Mai 2023 até Mai 2024